June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

European trust in AstraZeneca COVID-19 vaccine plunges, poll shows

Published 2021-03-21, 08:11 p/m
© Reuters. Italy resumes AstraZeneca COVID-19 vaccinations, in Turin
PFE
-
AZN
-

By Kate Kelland

LONDON (Reuters) - Confidence in the safety of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine has taken a big hit in Spain, Germany, France and Italy as reports of rare blood clots have been linked to it and many countries briefly stopped using it, poll data showed on Monday.

The polling firm YouGov said it had already found in late February that Europeans were more hesitant about the AstraZeneca vaccine than about those from Pfizer (NYSE:PFE) Inc/BioNTech and Moderna Inc, and that the clot concerns had further damaged public perceptions of the AstraZeneca shot's safety.

At least 13 European countries in the past two weeks stopped administering the AstraZeneca shot, co-developed with scientists at Oxford University, after reports of a small number of blood disorders.

Many resumed its use on Friday after the European Medicines Agency regulator said in a preliminary safety review on Thursday that the vaccine was safe and effective and not linked with a rise in the overall risk of blood clots.

EMA did not rule out a possible link, however, with rare cases of blood clots in the brain known as cerebral venous sinus thrombosis (CVST).

YouGov's poll - which covered about 8,000 people in seven European countries between March 12 and 18 - found that in France, Germany, Spain and Italy, people were now more likely to see the AstraZeneca vaccine as unsafe than as safe.

Some 55% of Germans say it is unsafe, while less than a third think it is safe, the poll showed. In France, where AstraZeneca's COVID vaccine was already unpopular, 61% of people polled say they now see it as unsafe.

In Italy and Spain, most people previously felt the AstraZeneca vaccine was safe - at 54% and 59% respectively - but those rates have fallen to 36% and 38% respectively, in the latest poll.

The survey showed that only in Britain, where the AstraZeneca COVID-19 vaccine has been used in a national rollout since January, have the blood clot concerns had little to no impact on public confidence. The majority of people polled in the UK - 77% - still say the shot is safe. Their trust in it is on a par with Pfizer's 79% perceived safety rating.

© Reuters. Italy resumes AstraZeneca COVID-19 vaccinations, in Turin

YouGov also said there appeared to be no spillover concerns across the seven European countries polled for the Pfizer and Moderna COVID-19 vaccines, both of which were seen as being as safe as in a poll three weeks ago.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.